STAAR Surgical (STAA) Expected to Announce Earnings on Tuesday

STAAR Surgical (NASDAQ:STAA) is anticipated to post its Q4 2025 results before the market opens on Tuesday, February 10th. Analysts expect STAAR Surgical to post earnings of $0.14 per share and revenue of $75.5370 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 17, 2026 at 12:00 AM ET.

STAAR Surgical Stock Performance

NASDAQ:STAA opened at $18.04 on Tuesday. The stock has a 50-day simple moving average of $23.00 and a two-hundred day simple moving average of $24.84. The firm has a market capitalization of $897.35 million, a PE ratio of -9.25 and a beta of 1.00. STAAR Surgical has a 52-week low of $13.50 and a 52-week high of $30.81.

Analyst Upgrades and Downgrades

STAA has been the subject of a number of recent research reports. BTIG Research reiterated a “neutral” rating on shares of STAAR Surgical in a research note on Tuesday, January 6th. Piper Sandler reissued a “neutral” rating on shares of STAAR Surgical in a research note on Monday, October 27th. Wells Fargo & Company raised their price objective on shares of STAAR Surgical from $28.00 to $30.75 and gave the company an “equal weight” rating in a research report on Wednesday, December 10th. Canaccord Genuity Group dropped their target price on shares of STAAR Surgical from $30.75 to $22.00 and set a “hold” rating for the company in a report on Thursday, January 15th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of STAAR Surgical in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $20.78.

Insider Transactions at STAAR Surgical

In related news, major shareholder Broadwood Partners, L.P. purchased 27,485 shares of the firm’s stock in a transaction on Friday, January 9th. The shares were acquired at an average price of $22.05 per share, for a total transaction of $606,044.25. Following the purchase, the insider directly owned 15,453,629 shares in the company, valued at $340,752,519.45. This trade represents a 0.18% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders have acquired 1,934,138 shares of company stock valued at $50,485,791. Insiders own 0.59% of the company’s stock.

Institutional Investors Weigh In On STAAR Surgical

Hedge funds have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd boosted its stake in STAAR Surgical by 2,605.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 1,016 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of STAAR Surgical by 9,928.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,513 shares of the medical instruments supplier’s stock worth $121,000 after acquiring an additional 4,468 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of STAAR Surgical by 375.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,919 shares of the medical instruments supplier’s stock valued at $99,000 after acquiring an additional 4,673 shares during the last quarter. CIBC Bancorp USA Inc. purchased a new position in shares of STAAR Surgical in the third quarter valued at $208,000. Finally, Amundi purchased a new position in shares of STAAR Surgical in the third quarter valued at $251,000. 96.70% of the stock is currently owned by hedge funds and other institutional investors.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.